‘The Cardiovascular Market Outlook to 2013' is a new report  published by Business Insights

The Cardiovascular Market Outlook to 2013

The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer's Lipitor, Sanofi's Plavix and Lovenox, and Amgen's Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape.

Anti-hypertensives were the highest selling sub-therapeutic category in 2007. Norvasc was the leading anti-hypertensive, with sales of $3.3bn. The global market for anticoagulants will experience significant activity over the next two years with the entry of new drugs including Boehringer Ingelheim's Pradaxa/Rendix, Bayer-Schering /J&J's Xarelto, BMS/Pfizer's apixaban and Eli Lilly/Daiichi's Effient. Crestor has been steadily gaining market share and positive JUPITER trial results will help to further improve its market position. The positive trial data is likely to result in recommended cholesterol treatment goals becoming lowered, and Crestor will be well positioned to capture more patients and expand the market. GlaxoSmithKline's (GSK) acquisition of Reliant Pharma will contribute to GSK having the highest growth amongst the leading players through to 2013. The addition of key drugs such as Lovazato GSK's portfolio will drive this growth. The anti-arrhythmic market is expected to remain a relatively small opportunity, as drug therapy has significant limitations Leading cholesterol-lowering drugs show declining sales. Patent expirations have been off-setting positive drivers of growth including recent trial results that support aggressive LDL lowering in broader patient populations.

The availability of generic simvastatin has resulted in increased therapeutic substitution and declining brand share. Stalling growth of leading hypertension drugs. Angiotensin receptor blockers or ARBs have become the most prescribed antihypertensive class. However after several years of gaining market, growth in the branded ARB category appears to be stalling. A number of studies have shown ARBs to be no more effective than generic ACE inhibitors, most recently the ONTARGET study published in April, 2008. Novel oral anti-thrombotics threaten leading drugs. Novel drugs in the thrombosis market pipeline are expected to strongly compete with the current market leader Lovenox .

The new drugs are orally formulated and are expected to substantially expand the market.Trial data has shown these drugs to be more efficacious without presenting a huge inrease in the risk of bleeding. Figure 5.13: Sales of key players in the cardiovascular market, ($m), 2007 "Pfizer registered a 6% decline in its year-on-year sales, largely driven by a drop in sales of its leading drugs; Norvasc due to its patent expiry and Lipitor due to multiple factors (discussed later in the chapter). Sales of the next major player, Sanof Aventis, grew by 9.2%, supported by its strong antithrombotics franchise, led by Lovenox and Plavix..." • Which indications will experience the greatest growth in the global cardiovascular market over the period 2008-13? • Which companies will become the key playersin the cardiovascular area over the period 2009 -13? • How have recent major product launches from companies such asGilead and Novartis performed? • Which pipeline products offer the highest growth potential? • What is the forecast market size and growth rate over the period 2008-2013 across the major cardiovascular indications? • What will be the competitive landscape of hypertension, dyslipidemia, thrombosis, hematology and cardiac therapies in 2013?